| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 214 |
| 1 | CYCLOPHOSPHAMIDE | 95 |
| 2 | CYCLOPHOSPHAMIDE FOR INJECTION | 95 |
| 3 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 95 |
| 4 | DOXORUBICIN | 92 |
| 5 | PREDNISONE | 56 |
| 6 | PREDNISOLONE | 51 |
| 7 | PREDNISOLONE ORAL | 51 |
| 8 | PREDNISOLONE ORAL SOLUTION | 51 |
| 9 | OBINUTUZUMAB | 40 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ZANUBRUTINIB | 24 | 0.0053 |
| 1 | ETOPOSIDE PHOSPHATE | 7 | 0.0043 |
| 2 | BENDAMUSTINE HYDROCHLORIDE | 36 | 0.0042 |
| 3 | IBRITUMOMAB TIUXETAN | 6 | 0.0039 |
| 4 | POLATUZUMAB VEDOTIN | 40 | 0.0039 |
| 5 | AVELUMAB | 15 | 0.0037 |
| 6 | SUTIMLIMAB-JOME | 1 | 0.0031 |
| 7 | IDELALISIB | 19 | 0.0027 |
| 8 | BENDAMUSTINE HCL | 38 | 0.0024 |
| 9 | OBINUTUZUMAB | 40 | 0.0024 |
| # | Drug class | Count |
|---|---|---|
| 0 | CD20-directed Cytolytic Antibody [EPC] | 238 |
| 1 | Corticosteroid [EPC] | 122 |
| 2 | Alkylating Drug [EPC] | 99 |
| 3 | Kinase Inhibitor [EPC] | 56 |
| 4 | Platinum-based Drug [EPC] | 34 |
| 5 | Topoisomerase Inhibitor [EPC] | 32 |
| 6 | Nucleoside Metabolic Inhibitor [EPC] | 22 |
| 7 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 19 |
| 8 | Folate Analog Metabolic Inhibitor [EPC] | 18 |
| 9 | Programmed Death Ligand-1 Blocker [EPC] | 15 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Classical Complement Pathway Inhibitor [EPC] | 1 | 0.0031 |
| 1 | Chemokine Receptor Type 4 Interaction [EPC] | 3 | 0.0022 |
| 2 | CD20-directed Cytolytic Antibody [EPC] | 238 | 0.0008 |
| 3 | Programmed Death Ligand-1 Blocker [EPC] | 15 | 0.0007 |
| 4 | Topoisomerase Inhibitor [EPC] | 32 | 0.0004 |
| 5 | Alkylating Drug [EPC] | 99 | 0.0004 |
| 6 | CD52-directed Cytolytic Antibody [EPC] | 7 | 0.0004 |
| 7 | Antimetabolite Immunosuppressant [EPC] | 6 | 0.0003 |
| 8 | Interleukin-17A Antagonist [EPC] | 10 | 0.0003 |
| 9 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 1 | 0.0002 |